Ivonescimab (AK112)

About Akeso

Founded in 2012, Akeso has established itself as a cornerstone of China's biopharmaceutical innovation, with a mission to develop world-class, first-in-class and best-in-class therapies. Its achievements include the global firsts of PD-1/CTLA-4 (cadonilimab) and PD-1/VEGF (ivonescimab) bispecific antibodies, a landmark $5B+ out-licensing deal, and FDA approval for its PD-1 inhibitor. The company's strategy leverages its integrated ACE Platform for end-to-end drug development, aggressive global partnerships, and a diversified pipeline spanning oncology, autoimmunity, and metabolic diseases to drive sustainable growth.

About Akeso

Founded in 2012, Akeso has established itself as a cornerstone of China's biopharmaceutical innovation, with a mission to develop world-class, first-in-class and best-in-class therapies. Its achievements include the global firsts of PD-1/CTLA-4 (cadonilimab) and PD-1/VEGF (ivonescimab) bispecific antibodies, a landmark $5B+ out-licensing deal, and FDA approval for its PD-1 inhibitor. The company's strategy leverages its integrated ACE Platform for end-to-end drug development, aggressive global partnerships, and a diversified pipeline spanning oncology, autoimmunity, and metabolic diseases to drive sustainable growth.

About Akeso

Founded in 2012, Akeso has established itself as a cornerstone of China's biopharmaceutical innovation, with a mission to develop world-class, first-in-class and best-in-class therapies. Its achievements include the global firsts of PD-1/CTLA-4 (cadonilimab) and PD-1/VEGF (ivonescimab) bispecific antibodies, a landmark $5B+ out-licensing deal, and FDA approval for its PD-1 inhibitor. The company's strategy leverages its integrated ACE Platform for end-to-end drug development, aggressive global partnerships, and a diversified pipeline spanning oncology, autoimmunity, and metabolic diseases to drive sustainable growth.

About Summit Therapeutics

Summit Therapeutics' mission is to develop and commercialize innovative medicines for serious unmet medical needs, with a strategic focus on oncology and infectious diseases. Its key achievement is the advancement of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, into pivotal Phase III trials for non-small cell lung cancer (NSCLC). The company's strategy combines strategic asset acquisition with focused clinical development to build value through high-potential, late-stage programs. Summit's significant market valuation reflects investor confidence in its lead asset's differentiated profile and blockbuster potential.

About Summit Therapeutics

Summit Therapeutics' mission is to develop and commercialize innovative medicines for serious unmet medical needs, with a strategic focus on oncology and infectious diseases. Its key achievement is the advancement of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, into pivotal Phase III trials for non-small cell lung cancer (NSCLC). The company's strategy combines strategic asset acquisition with focused clinical development to build value through high-potential, late-stage programs. Summit's significant market valuation reflects investor confidence in its lead asset's differentiated profile and blockbuster potential.

Therapeutic Areas